TAE Life Sciences (TLS), a leader in boron neutron capture therapy (BNCT) technology, and Stella Pharma, the pioneering developer of the boronophenylalanine (BPA) drug Steboronine®, are pleased to announce an exclusive strategic collaboration aimed at expanding the development, commercialization, and adoption of BNCT using BPA in the U.S. and European markets. The collaboration will also focus on the clinical and regulatory advancement of BNCT for various cancers, including head and neck, brain, skin, breast, esophagus, and lung cancers.

Stella Pharma’s BPA drug is the world’s first clinically approved boron drug for BNCT, with Japan being the first country to approve BNCT for head and neck cancer treatment using Steboronine®. As the global leader in BPA production, Stella Pharma has now partnered with TAE Life Sciences to broaden the availability of BNCT therapy to U.S. and European patients, marking a significant step in the global adoption of this revolutionary cancer treatment.

A Strategic Collaboration to Expand BNCT’s Global Reach

The collaboration’s primary objective is to accelerate the development and commercialization of BPA-based BNCT in the U.S. and Europe. TLS will serve as the exclusive commercial partner for Stella Pharma’s BPA drug in these regions, with plans for clinical trials to commence in 2026. This partnership will help bring BNCT’s proven benefits to healthcare institutions in the U.S. and Europe, significantly increasing patient access to this innovative treatment.

“Our partnership with Stella Pharma is a milestone in our mission to advance BNCT as a powerful cancer treatment for patients around the world,” said Rob Hill, CEO of TAE Life Sciences. “We are thrilled to be the exclusive commercial partner for BPA in the U.S. and Europe and to support the wider adoption of BNCT globally. This collaboration is a major step toward offering a transformative solution for patients with hard-to-treat cancers.”

A Unified Approach to Cancer Treatment

In addition to the development and commercialization of BNCT and BPA, both companies are committed to supporting BNCT equipment vendors in implementing BPA-based treatments. The collaboration will foster partnerships with BNCT equipment vendors across multiple regions, creating a comprehensive ecosystem to support the adoption of BNCT therapies. This includes expanding clinical trials for recurrent head and neck cancers and exploring new clinical applications for other cancer types.

“Our partnership with TAE Life Sciences is an exciting opportunity to bring the benefits of BPA-based BNCT to patients in the U.S. and Europe,” said Koki Uehara, President and Chief Operating Officer of Stella Pharma. “Together, we are committed to making BNCT a standard-of-care treatment option for patients with cancers that are difficult to treat. We look forward to advancing this promising technology and improving outcomes for cancer patients worldwide.”

A Vision for the Future of Cancer Treatment

The collaboration between Stella Pharma and TAE Life Sciences is designed to explore and advance the potential of BNCT in treating a wide array of hard-to-treat cancers. By combining expertise in BNCT technology, drug development, and international commercialization, the partnership aims to expand treatment options for cancer patients and ultimately improve survival rates and quality of life.

“BNCT represents a breakthrough approach to cancer treatment, and together with Stella Pharma, we are committed to driving innovation and improving patient outcomes,” added Rob Hill. “We are excited to explore additional collaboration opportunities and to continue expanding the global reach of BNCT therapies.”